tenofoviiri

Tenofoviir is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV-1 infection. It was developed by ViiV Healthcare and is marketed under the brand name Viread. Tenofoviir works by inhibiting the reverse transcriptase enzyme, which is essential for the replication of HIV-1. This inhibition prevents the virus from integrating its genetic material into the host cell's DNA, thereby stopping the viral replication process.

Tenofoviir is typically used in combination with other antiretroviral drugs to form a complete antiviral regimen. It is often prescribed as part of a fixed-dose combination (FDC) with emtricitabine, a nucleoside reverse transcriptase inhibitor, under the trade name Truvada. This combination is widely used for pre-exposure prophylaxis (PrEP) to prevent HIV transmission and for treatment as post-exposure prophylaxis (PEP) after potential exposure to HIV.

The use of tenofoviir has been associated with several side effects, including gastrointestinal disturbances, headache, and rash. Serious adverse reactions are rare but can include lactic acidosis, a condition characterized by an excess of lactic acid in the blood, which can be life-threatening if not treated promptly.

Tenofoviir is available in various formulations, including tablets and oral solutions, to accommodate different patient needs. Its efficacy and safety profile have been extensively studied, and it is considered a valuable component in the HIV treatment arsenal. However, like all antiretroviral medications, tenofoviir should be used under the guidance of healthcare professionals to ensure optimal treatment outcomes and minimize potential risks.